Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Amifostine to Protect From the Side Effects of Peripheral Stem Cell Transplantation in Treating Patients With High-Risk or Relapsed Solid Tumors
This study has been terminated.
( Withdrawn due to slow accrual )
Study NCT00003926 Information provided by National Cancer Institute (NCI)
First Received: November 1, 1999 Last Updated: August 31, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cancer-related Problem/Condition
Childhood Germ Cell Tumor
Chordoma
Extragonadal Germ Cell Tumor
Kidney Cancer
Liver Cancer
Neuroblastoma
Ovarian Cancer
Retinoblastoma
Sarcoma
Testicular Germ Cell Tumor
Additional conditions recognized in this trial
Carcinoma, Renal Cell
Central Nervous System Neoplasms
Kidney Neoplasms
Liver Neoplasms
Neoplasms, Germ Cell and Embryonal
Nervous System Neoplasms
Neuroectodermal Tumors, Primitive, Peripheral
Ovarian Neoplasms
More general conditions related to this trial
Adenocarcinoma
Adnexal Diseases
Carcinoma
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Eye Diseases
Eye Neoplasms
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Kidney Diseases
Liver Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Connective and Soft Tissue
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Nervous System Diseases
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Ovarian Diseases
Retinal Diseases
Retinal Neoplasms
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
amifostine trihydrate
busulfan
filgrastim
melphalan
thiotepa
Additional drug interventions recognized in this trial
Amifostine
More general drug interventions related to this trial
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Radiation-Protective Agents
Therapeutic Uses
Sponsors listed in this trial
Masonic Cancer Center, University of Minnesota
Back to top of Main Content
